[A23-22] Daridorexant (insomnia) – Addendum to Commission A22-123
Last updated 12.05.2023
Project no.:
A23-22
Commission:
Commission awarded on 28.03.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-123 | Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
2023-05-D12 A G-BA decision was published.
G-BA documents on this decision